孟鲁司特钠联合布地奈德治疗对小儿慢性咳嗽效果观察

Effect of Montelukast Sodium Combined with Budesonide on Chronic Cough in Children

目的:探讨孟鲁司特钠联合布地奈德治疗小儿慢性咳嗽的临床效果。方法:选取220例2017年2月-2018年2月在本院治疗的慢性咳嗽患儿,按随机数字表法分为对照组和观察组,每组110例。对照组给予单纯布地奈德治疗,观察组在对照组的基础上给予孟鲁司特钠治疗,两组均治疗4周。观察并比较两组治疗前后血清免疫球蛋白E(IgE)、嗜酸性粒细胞计数(EOS)、嗜酸性粒细胞阳离子蛋白(ECP)水平、临床治疗效果、肺功能指标以及不良反应发生率。结果:治疗前两组IgE、EOS、ECP比较,差异均无统计学意义(P>0.05);治疗后,两组IgE、EOS、ECP均低于治疗前(P<0.05),观察组IgE(272.56±35.84)μg/L、ECP(6.08±1.37)μg/L、EOS(0.41±0.07)×109/L均低于对照组(432.74±48.25)μg/L、(12.64±2.68)μg/L、(0.71±0.13)×109/L(P<0.05);观察组治疗总有效率(94.55%)高于对照组(73.64%),差异有统计学意义(P<0.05)。治疗前,两组用力呼气容积(forced expiratory volume in one second,FEV1)、用力肺活量(forced vital capacity,FVC)、呼气峰流速(peak expiratory flow,PEF)比较,差异均无统计学意义(P>0.05),治疗后,两组FEV1、FVC、PEF均高于治疗前(P<0.05),观察组FEV1、FVC、PEF均高于对照组(P<0.05)。观察组不良反应发生率(4.55%)与对照组(5.45%)比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合布地奈德治疗小儿慢性咳嗽,不但能够有效降低患儿的气道反应和炎症反应,改善患儿的免疫机能和肺功能,并且对提高患儿的通气功能以及治疗效果,降低并发症的发生率等均有显著效果,有推广价值。

Objective:To investigate the clinical effect of Montelukast Sodium combined with Budesonide in the treatment of children with chronic cough.Method:A total of 220 children with chronic cough treated in our hospital from February 2017 to February 2018 were divided into control group and observation group according to the random number table method,110 cases in each group.The control group was treated with Budesonide alone,and the observation group was treated with Montelukast Sodium on the basis of the control group,the two groups were treated for 4 weeks.The serum immunoglobulin E(IgE),eosinophilic granulocyte count(EOS),eosinophilic cationic protein(ECP)levels,clinical efficacy,pulmonary function indicators and adverse reactions were observed and compared between the two groups before and after treatment.Result:There was no significant difference in IgE,EOS,ECP between the two groups before treatment(P>0.05).After treatment,the IgE,EOS and ECP in two groups were lower than those before treatment(P<0.05),IgE(272.56±35.84)μg/L,ECP(6.08±1.37)μg/L,EOS(0.41±0.07)×109/L in the observation group were lower than those in the control group(432.74±48.25)μg/L,(12.64±2.68)μg/L,(0.71±0.13)×109/L(P<0.05).The total effective rate of the observation group(94.55%)was higher than that of the control group(73.64%),the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in forced expiratory volume in one second(FEV1),forced vital capacity(FVC),peak expiratory flow(PEF)between the two groups(P>0.05).After treatment,FEV1,FVC and PEF in two groups were higher than those before treatment(P<0.05),FEV1,FVC and PEF in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group(4.55%)and the control group(5.45%)was compared,the differences were not statistically significant(P>0.05).Conclusion:Montelukast Sodium combined with Budesonide in the treatment of chronic cough in children can not only effectively reduce the airway response and inflammatory response,but also improve the immune function and lung function of the child,improve the children’s ventilation function and treatment effect,reduce the incidence of complications have significant effects,which has promotional value.